Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research interests include Sarcoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Advanced Breast Cancer Therapies, and Vascular Tumors and Angiosarcomas.
Fifth subtype of Kaposi sarcoma in HIV-negative MSM: a retrospective single-arm cohort study from a tertiary care center in NYC from 2000 to 2022
Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial
Phase II Trial of <i>nab-</i>Sirolimus in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (AMPECT): Long-Term Efficacy and Safety Update
Histology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma
A Phase II Study of Epacadostat and Pembrolizumab in Patients with Advanced Sarcoma
Therapy-Induced Senescence Contributes to the Efficacy of Abemaciclib in Patients with Dedifferentiated Liposarcoma
Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets
Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma
Clinical, genomic, and transcriptomic correlates of response to immune checkpoint blockade-based therapy in a cohort of patients with angiosarcoma treated at a single center
Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial
<i>nab</i>-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab
Early treatment-related neutropenia predicts response to palbociclib
Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans
Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma.
Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer
A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
ATRX is a regulator of therapy induced senescence in human cells
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With <i>CDK4</i> Inhibitor Palbociclib
Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab
Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma
Safety, tolerability, efficacy and pharmacodynamics of the selective JAK1 inhibitor GSK2586184 in patients with systemic lupus erythematosus
Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications
MDM2 turnover and expression of ATRX determine the choice between quiescence and senescence in response to CDK4 inhibition
Impact of surgery, radiation and systemic therapy on the outcomes of patients with dendritic cell and histiocytic sarcomas
Kaposi Sarcoma of Childhood: Inborn or Acquired Immunodeficiency to Oncogenic HHV‐8